Reactivity of monoclonal antibody FC-2.15 against drug resistant breast cancer cells. Additive cytotoxicity of adriamycin and taxol with FC-2.15

Breast Cancer Research and Treatment

Volumn 47, Issue 2, 1998, Pages 163-170

  Ballare C ^a   Portela, P ^b   Schiaffi, J ^c   Yomha, R ^c   Mordoh, J ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^c Hospital Bernardino Rivadavia   (Argentina)

Author keywords

Adriamycin; Breast cancer; MDR; Monoclonal antibody; Taxol

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; COMPLEMENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; PACLITAXEL; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD GROUP LEWIS SYSTEM; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD15; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 0031963756     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005949118919     Document Type: Article

References (23)

1. Mordoh J, Leis S, Bravo AI, Podhajcer O, Ballaré C, Capurro M, Kairiyama C, Bover L: Description of a new monoclonal antibody, FC-2.15, reactive with human breast cancer and other human neoplasias. Int J Biol Markers 9: 125-134, 1994
2. Capurro M, Bover L, Portela P, Livingston P, Mordoh J: FC-2.15, a monoclonal antibody active against human breast cancer, specifically recognizes Lewis x hapten. Cancer Immunol Immunother (in press)
3. Ballaré C, Barrio M, Portela P, Mordoh J: Functional properties of FC-2.15, a monoclonal antibody that mediates human complement cytotoxicity against breast cancer cells. Cancer Immunol Immunother 41: 15-22, 1995
4. Mordoh J, Silva C, Albarellos M, Bravo AI, Kairiyama C: Phase I clinical trial in cancer patients of a new monoclonal antibody FC-2.15 reacting with tumor proliferating cells. J Immunother 17: 151-160, 1995
5. McClean S, Hill BT: An overview of membrane, cytosolic and nuclear proteins associated with the expression of resistance to multiple drugs in vitro. Biochim Biophys Acta 1114: 107-127, 1992
6. Fairchild C, Ivy SP, Kao-Shan C, Whang-Peng J, Rosen N, Israel M, Melera P, Cowan K, Goldsmith M: Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res 47: 5141-5148, 1987
7. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993
8. Salmon S, Grogan T, Miller T, Scheper R, Dalton W: Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 81: 696-701, 1989
9. Vickers PJ, Dickson RB, Shoemaker R, Cowan KH: A multidrug - resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol 2: 886-892, 1988
10. Whelan RD, Hill BT: Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation. Breast Cancer Res Treat 26: 23-39, 1993
11. Soule HD, Vazquez J, Long A, Albert S, Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409-1415, 1973
12. Bover L, Barrio M, Slavutsky I, Bravo AI, Quintans C, Bagnati A, Lema B, Schiaffi J, Yomha R, Mordoh J: Description of a new human breast cancer cell line, IIB-BR-G, established from a primary undifferentiated tumor. Breast Cancer Res Treat 19: 47-56, 1991
13. Bravo AI, Sorin I, Guman N, Mordoh J: Carcinoembryonic antigen and differentiation in human breast cancer. J Exp Clin Cancer Res 4: 3-10, 1985
14. Hakomori S: Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 45: 2405-2414, 1985
15. Kim YS: Altered glycosylation of mucin glycoproteins in colonic neoplasia. J Cell Biochem (Suppl) 16G: 91-96, 1992
16. Kim YS: Carbohydrate antigen expression in colorectal cancer. Sem Cancer Biol 1: 189-197, 1990
17. Ho SB, Kim YS: Carbohydrate antigens on cancer-associated mucin-like molecules. Sem Cancer Biol 2: 389-400, 1991
18. Urdal DL, Brentnall TA, Bernstein ID, Hakomori SI: A granulocyte reactive monoclonal antibody, IG10, identifies the galbl-4 (Fucal-3) GlcNAc (x determinant) expressed in HL60 cells on both glycolipid and glycoprotein molecules. Blood 62: 1022-1026, 1983
19. x-containing glycoproteins and glycolipids in sera of patients with adenocarcinoma. Cancer Res 50: 1375-1380, 1990
20. Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO, Livingston PO: Selection of tumor antigens as targets for immune attack using immunohistochemistry. Blood group-related antigens. Int J Cancer (in press).
21. D'Arpa P, Liu LF: Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989: 163-177, 1989
22. Hudis C, Seldman A, Raptis G, Fennelly D, Gilewski T, Baselga J, Theodoulou M, Sklarin N, Moynahan M, Surbone A, Currie V, Lebwohl D, Uhlenhopp M, Crown J, Norton L: Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 23: 58-64, 1996
23. Jordan MA, Toso RJ, Thrower D, Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90:9552-9556, 1993